Biosimilars: the debate continues.
作者信息
Colbert Robert A, Cronstein Bruce N
机构信息
Pediatric Translational Research Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland 20892, USA.
出版信息
Arthritis Rheum. 2011 Oct;63(10):2848-50. doi: 10.1002/art.30505.
Abstract
摘要
相似文献
1
Biosimilars: the debate continues.生物类似药：争论仍在继续。
Arthritis Rheum. 2011 Oct;63(10):2848-50. doi: 10.1002/art.30505.
2
The Experience with Biosimilars of Infliximab in Rheumatic Diseases.类风湿性疾病中应用英夫利昔单抗生物类似药的经验。
Curr Pharm Des. 2017;23(44):6752-6758. doi: 10.2174/1381612824666171129192040.
3
Infection and Malignancy in Rheumatic Diseases.风湿性疾病中的感染与恶性肿瘤
Rheum Dis Clin North Am. 2017 Feb;43(1):xi-xii. doi: 10.1016/j.rdc.2016.10.002.
4
Biosimilars: how similar?生物类似药：有多相似？
Intern Med J. 2014 Mar;44(3):218-23. doi: 10.1111/imj.12292.
5
Infection and Malignancy in Rheumatic Diseases.风湿性疾病中的感染与恶性肿瘤
Rheum Dis Clin North Am. 2017 Feb;43(1):xiii-xiv. doi: 10.1016/j.rdc.2016.10.001.
6
PANLAR consensus statement on biosimilars.泛欧共识声明：关于生物类似药。
Clin Rheumatol. 2019 May;38(5):1485-1496. doi: 10.1007/s10067-019-04496-3. Epub 2019 Mar 27.
7
Biosimilars in rheumatology: current perspectives and lessons learnt.风湿病学中的生物类似药：当前的观点和经验教训。
Nat Rev Rheumatol. 2015 Dec;11(12):713-24. doi: 10.1038/nrrheum.2015.110. Epub 2015 Aug 18.
8
Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases.满足未满足的临床需求：生物类似药在治疗风湿性疾病中的潜力。
Rheumatology (Oxford). 2017 Aug 1;56(suppl_4):iv1-iv3. doi: 10.1093/rheumatology/kex275.
9
The future landscape of biosimilars in rheumatology: Where we are where we are going.生物类似药在风湿病学领域的未来前景：我们所处的位置和我们的去向。
Autoimmun Rev. 2019 Feb;18(2):203-208. doi: 10.1016/j.autrev.2018.09.005. Epub 2018 Dec 18.
10
Switching to biosimilars in the treatment of rheumatic diseases.切换至生物类似药治疗风湿性疾病。
Expert Rev Clin Immunol. 2018 Jul;14(7):557-571. doi: 10.1080/1744666X.2018.1490178. Epub 2018 Jul 13.
引用本文的文献
1
Biosimilars in rare diseases: a focus on paroxysmal nocturnal hemoglobinuria.罕见病中的生物类似药：以阵发性睡眠性血红蛋白尿为例。
Haematologica. 2023 May 1;108(5):1232-1243. doi: 10.3324/haematol.2022.281562.
2
Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.美国已上市的癌症支持性治疗生物类似药的安全性：利用食品和药物管理局不良事件报告系统（FAERS）数据库进行的比例失调分析。
BioDrugs. 2021 Mar;35(2):239-254. doi: 10.1007/s40259-020-00466-3. Epub 2021 Jan 13.
3
Knowledge, Attitude, and Practice Towards Biosimilars and Interchangeable Products: A Prescriptive Insight by the Pharmacists.药剂师对生物类似药和可互换产品的认知、态度及实践：一项规范性见解
Int J Gen Med. 2020 Nov 11;13:1075-1082. doi: 10.2147/IJGM.S266545. eCollection 2020.
4
The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy.生物类似药的突破：生物治疗叙事的转折。
Biomolecules. 2019 Aug 24;9(9):410. doi: 10.3390/biom9090410.
5
Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community.建立生物类似药的全面证据：监管考量及增强医疗界的信心
BioDrugs. 2017 Jun;31(3):175-187. doi: 10.1007/s40259-017-0218-5.
6
Patient attitudes and understanding about biosimilars: an international cross-sectional survey.患者对生物类似药的态度和认知：一项国际横断面调查。
Patient Prefer Adherence. 2016 May 26;10:937-48. doi: 10.2147/PPA.S104891. eCollection 2016.
7
Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists.对后续进入市场的生物制剂/生物类似药的态度：一项对加拿大风湿病学家的调查。
Clin Rheumatol. 2015 Aug;34(8):1427-33. doi: 10.1007/s10067-014-2835-4. Epub 2015 Jan 15.
8
Subsequent entry biologics/biosimilars: a viewpoint from Canada.后续的生物制剂/生物类似药进入市场：来自加拿大的观点。
Clin Rheumatol. 2012 Sep;31(9):1289-92. doi: 10.1007/s10067-012-2066-5. Epub 2012 Aug 26.
9
Biosimilars in rheumatology: a view from Latin America.风湿病学中的生物类似药：来自拉丁美洲的视角。
Clin Rheumatol. 2012 Sep;31(9):1279-80. doi: 10.1007/s10067-012-2068-3. Epub 2012 Aug 24.
本文引用的文献
1
Biosimilars encircle Rituxan, US debates innovator exclusivity.生物类似药包围了美罗华，美国热议创新药独占权。
Nat Biotechnol. 2011 Mar;29(3):177-8. doi: 10.1038/nbt0311-177.
2
Similarity trials.相似性试验
Nat Biotechnol. 2011 Jan;29(1):1. doi: 10.1038/nbt.1760.
3
Hearing shines spotlight on biosimilar controversies.听证会聚焦生物类似药争议。
Nat Rev Drug Discov. 2010 Dec;9(12):905-6. doi: 10.1038/nrd3325.
4
Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.生物类似物 epoetins 和其他“后续”生物制剂：欧洲经验更新。
Am J Hematol. 2010 Oct;85(10):771-80. doi: 10.1002/ajh.21805.
Zotero 插件